Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach

References

• Han R, Zhou J. Disease burden of hepatitis c infection in Asia: an overview of systematic review. Value Health. 2018;21:S63.
   Web of Science ®Google Scholar
• Han R, Zhou J. Comparison of clinical burden of Hcv infection between Asia and Europe: an overview of systematic review. Value Health. 2018;21:S63.
   Web of Science ®Google Scholar
• Han R, Zhou J. Humanistic and economic burden of HCV infection: an overview of systematic review. Value in Health. 2018;21:S65–S66.
   Google Scholar
• Han R, Zhou J, François C, et al. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. BMC Infect Dis. 2019;19(1):655.
   Web of Science ®Google Scholar
• Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418–14.
   PubMed Web of Science ®Google Scholar
• Butt AA, Yan P, Lo Re V 3rd, et al.Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2015;175(2):178–185.
   PubMed Web of Science ®Google Scholar
• Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis. 2011;31(4):331–339.
   PubMed Web of Science ®Google Scholar
• European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325–336.
   PubMed Web of Science ®Google Scholar
• Hatzakis A, Lazarus JV, Cholongitas E, et al. Securing sustainable funding for viral hepatitis elimination plans. Liver Int. 2020;40(2):260–270.
   Web of Science ®Google Scholar
• Harris HE, Harris R CA, Mandal S. Hepatitis C in England, 2019 report: working to eliminate hepatitis C as a major public health threat. London: Public Health England; 2019.
   Google Scholar
• Harris HE, Costella A, Mandal S, et al. Hepatitis C treatment monitoring in England: Content, completeness and preliminary findings from the Hepatitis C patient registry and treatment outcome system. November 2018. Public Health England, London.
   Google Scholar
• NICE. Hepatitis B and C testing: people at risk of infection public health guideline 2012 Mar 2013; Available from: https://www.nice.org.uk/guidance/ph43.
   Google Scholar
• WHO. guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017.  License: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• Public Health England, H.P.S.. public health wales, and public health agency Northern Ireland, shooting up: infections among people who inject drugs in the UK 2016.. London: Public Health England; 2017.
   Google Scholar
• Nijmeijer BM, Koopsen J, Schinkel J, et al. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc. 2019;22(6):e25348.
   PubMedGoogle Scholar
• Martin NK, Foster GR, Vilar J, et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat. 2015;22(4):399–408.
   Web of Science ®Google Scholar
• NHS England. Operational delivery networks for hepatitis C care in adults. 2017. https://www.england.nhs.uk/wp-content/uploads/2018/08/Operational-delivery-networks-for-hepatitis-C-care-adult.pdf
   Google Scholar
• P.P.G.o.L.H.I. A. Report. All-party parliamentary group on liver health inquiry report, eliminating hepatitis C in England. All-Party Parliamentary Group on Liver Health. 2018.
   Google Scholar
• National institute for health and clinical excellence. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C [NICE technology appraisal guidance106]. Revised Nov 2007. Available from: http://www.nice.org.uk/nicemedia/live/11590/33534/33534.pdf Accessed 2019 Jul 22
   Google Scholar
• Han RZJ. PIN19 - a cost comparison of treating chronic hepatitis c patients with sofosbuvir-based regimens. Value Health. 2018;21:S224.
   Web of Science ®Google Scholar
• Marshall AD, Cunningham EB, Nielsen S, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3(2):125–133.
   PubMed Web of Science ®Google Scholar
• Martin NK, Vickerman P, Foster GR, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54(6):1137–1144.
   Web of Science ®Google Scholar
• Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58(5):1598–1609.
   PubMed Web of Science ®Google Scholar
• Martin NK, Thornton A, Hickman M, et al. Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the UK? epidemiological and modeling insights. Clin Infect Dis. 2016;62(9):1072–1080.
   PubMed Web of Science ®Google Scholar
• Thokala P, Dixon S, Jahn B. Resource modelling: the missing piece of the HTA jigsaw? Pharmacoeconomics. 2015;33(3):193–203.
   Web of Science ®Google Scholar
• Earnshaw S. Are We Ready to Use Constrained Optimization in Health Outcomes Research? Value Health. 2018 Sep;21(9):1029-1030.
   Google Scholar
• Ndiaye M, Alfares H. Modeling health care facility location for moving population groups. Comput Oper Res. 2008;35(7):2154–2161.
   Web of Science ®Google Scholar
• Araz C, Selim H, Ozkarahan I. A fuzzy multi-objective covering-based vehicle location model for emergency services. Comput Oper Res. 2007;34(3):705–726.
   Web of Science ®Google Scholar
• Verter V, Lapierre SD. Location of preventive health care facilities. Ann Oper Res. 2002;110(1–4):123–132.
   Web of Science ®Google Scholar
• Ehrgott, M., Güler, Ç., Hamacher, H.W. Mathematical optimization in intensity modulated radiation therapy. Ann Oper Res. 2010;175(1):309–365.
   Web of Science ®Google Scholar
• Bertsimas D, Farias VF, Trichakis N. Fairness, efficiency, and flexibility in organ allocation for kidney transplantation. Operations Research. 2013;61(1):73–87.
   Google Scholar
• Demarteau N, Breuer T, Standaert B. Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics. 2012;30(4):337–353.
   Web of Science ®Google Scholar
• Earnshaw SR, Richter A, Sorensen SW, et al. Optimal allocation of resources across four interventions for type 2 diabetes. Med Decis Making. 2002;22(5):S80–91. Suppl.
   Web of Science ®Google Scholar
• Alistar SS, Long EF, Brandeau ML, et al. HIV epidemic control-a model for optimal allocation of prevention and treatment resources. Health Care Manag Sci. 2014;17(2):162–181.
   Web of Science ®Google Scholar
• Brandeau ML, Zaric GS, Richter A. Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis. J Health Econ. 2003;22(4):575–598.
   PubMed Web of Science ®Google Scholar
• Lasry A, Sansom SL, Hicks KA, et al. Allocating HIV prevention funds in the USA: recommendations from an optimization model. PLoS One. 2012;7(6):e37545.
   Web of Science ®Google Scholar
• Lasry A, Richter A, Lutscher F. Recommendations for increasing the use of HIV/AIDS resource allocation models. BMC Public Health. 2009;9(1): S8.
   Google Scholar
• Lasry A, Sansom SL, Hicks KA, et al. A model for allocating CDC’s HIV prevention resources in the USA. Health Care Manag Sci. 2011;14(1):115–124.
   Web of Science ®Google Scholar
• Juusola JL, Brandeau ML. HIV treatment and prevention: a simple model to determine optimal investment. Med Decis Making. 2016;36(3):391–409.
   Web of Science ®Google Scholar
• Crown W, Buyukkaramikli N, Thokala P, et al. Constrained optimization methods in health services research-an introduction: report 1 of the ISPOR optimization methods emerging good practices task force. Value Health. 2017;20(3):310–319.
   PubMed Web of Science ®Google Scholar
• Crown W, Buyukkaramikli N, Sir MY, et al. Application of constrained optimization methods in health services research: report 2 of the ISPOR optimization methods emerging good practices task force. Value Health. 2018;21(9):1019–1028.
   PubMed Web of Science ®Google Scholar
• NICE National Institute for Health and Care Excellence. National institute for health and care excellence single technology appraisal Elbasvir-grazoprevir for treating chronic hepatitis C [ID842]. 2016.
   Google Scholar
• European centre for disease prevention and control. hepatitis B and C epidemiology in selected population groups in the EU/EEA. ECDC: Stockholm: 2018. https://www.ecdc.europa.eu/en/publications-data/hepatitis-b-and-c-epidemiology-selected-population-groups-eueea
   Google Scholar
• Macken L, Gelson W, Priest M, et al. Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort. J Med Virol. 2019;91(11):1979–1988.
   Web of Science ®Google Scholar
• Lauria DT, Maskery B, Poulos C, et al. An optimization model for reducing typhoid cases in developing countries without increasing public spending. Vaccine. 2009;27(10):1609–1621.
   PubMed Web of Science ®Google Scholar
• Becker NG, Starczak DN. Optimal vaccination strategies for a community of households. Math Biosci. 1997;139(2):117–132.
   Web of Science ®Google Scholar
• Busschots D, Toghanian S, Bielen R, et al. Eliminating viral hepatitis C in Belgium: the micro-elimination approach. BMC Infect Dis. 2020;20(1):181.
   Web of Science ®Google Scholar
• Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess. 2000;4(33):1–67.
   Google Scholar
• Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha-2a and −2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. 2004;8(39):iii–iv, 1–125.
   Google Scholar
• Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. 2007;11(11):1–205. iii.
   Web of Science ®Google Scholar
• Annemans L, Warie H, Nechelput M, et al. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients. Acta Gastroenterol Belg. 2004;67(1):1–8.
   Web of Science ®Google Scholar
• García-Contreras F, Nevárez-Sida A, Constantino-Casas P, et al. Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1. Arch Med Res. 2006;37(5):663–673.
   Web of Science ®Google Scholar
• Hornberger J, Farci P, Prati D, et al. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase. J Viral Hepat. 2006;13(6):377–386.
   Web of Science ®Google Scholar
• Lidgren M, Hollander A, Weiland O, et al. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life. Scand J Gastroenterol. 2007;42(7):867–877.
   PubMed Web of Science ®Google Scholar
• Lin WA, Tarn YH, Tang SL. Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naive Chinese patients with chronic hepatitis C. Aliment Pharmacol Ther. 2006;24(10):1483–1493.
   Web of Science ®Google Scholar
• Nakamura J, Kobayashi K, Toyabe S, et al. The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C. Eur J Gastroenterol Hepatol. 2007;19(9):733–739.
   Web of Science ®Google Scholar
• Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. Jama. 2003;290(2):228–237.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Jensen DM, Bernstein DE, et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol. 2004;99(8):1490–1496.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics. 2004;22(4):257–265.
   PubMed Web of Science ®Google Scholar
• Wong J, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg. 2002;65(2):110–111.
   Web of Science ®Google Scholar
• McEwan P, Kim R, Yuan Y. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy. 2013;11(1):53–63.
   Google Scholar
• Han R, François C, Toumi M. Systematic review of health state utility values used in european pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results. Applied Health Economics and Health Policy; 2020;19(1):29-44.
   Google Scholar
• Johnson SJ, et al. Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. J Med Econ. 2016;19(10):983–994.
   PubMed Web of Science ®Google Scholar
• Cornish R, et al. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK general practice research database. Bmj. 2010;341:c5475.
   PubMed Web of Science ®Google Scholar
• Aspinall EJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57(2):S80–9. Suppl.
   Google Scholar
• Latham NH, et al. Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs. Liver Int. 2019;39(12):2244–2260.
   Web of Science ®Google Scholar
• Fischer JA, et al. Quality of life of people who inject drugs: characteristics and comparisons with other population samples. Qual Life Res. 2013;22(8):2113–2121.
   PubMed Web of Science ®Google Scholar
• Dalgard O, et al. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology. 2004;39(1):74–80.
   PubMed Web of Science ®Google Scholar
• Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the USA. Addiction. 2001;96(9):1267–1278.
   PubMed Web of Science ®Google Scholar
• Helbling B, et al. Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut. 2008;57(11):1597–1603.
   Web of Science ®Google Scholar
• Richardson D, Fisher M, Sabin CA. Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infection. J Infect Dis. 2008;197(8): 1213–1214. author reply 1214-5.
   PubMed Web of Science ®Google Scholar
• Falade-Nwulia O, et al. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018;25(3):220–227.
   PubMed Web of Science ®Google Scholar
• Liu J, et al. The influence of social support on quality of life of men who have sex with men in China: a preliminary study. PLoS One. 2015;10(5):e0127644.
   Web of Science ®Google Scholar
• Safren SA, Blashill AJ, O’Cleirigh CM. Promoting the sexual health of MSM in the context of comorbid mental health problems. AIDS Behav. 2011;15(1): S30–4. Suppl.
   PubMedGoogle Scholar
• Zhang P, et al. Effect of chronic disease self-management program on the quality of life of HIV-infected men who have sex with men: an empirical study in Shanghai, China. Int J Health Plann Manage. 2019;34(3):1055–1064.
   Web of Science ®Google Scholar
• The National Institute for Health and Care Excellence. Excellence TNIFHAC. Guide to the methods of technology appraisal. 2013. https://www.nice.org.uk/process/pmg9/chapter/foreword
   Google Scholar
• McCarl BA, Apland J. Validation of linear programming models. 2016;18(2):155–164. Journal of Agricultural and Applied Economics, 1986;18(2):155-164.
   Google Scholar
• NHS England announces ‘huge investment’ for new hepatitis C treatments. Pharm J. June 20 2015;294(7867).
   Google Scholar
• Jin F, Matthews GV, Grulich AE. Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review. Sex Health. 2017;14(1):28–41.
   PubMed Web of Science ®Google Scholar
• Immunisation HBSD. Public health england operational delivery network (ODN) area profiles: data and provisional modelling of the HCV epidemic. Public Health England; 2018.
   Google Scholar
• Gompels M, et al. The use of funnel plots with regression as a tool to visually compare HIV treatment outcomes between centres adjusting for patient characteristics and size: a UK Collaborative HIV Cohort study. HIV Med. 2018;19(6):386–394.
   Web of Science ®Google Scholar
• Aspinall EJ, et al. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment. J Hepatol. 2015;62(2):269–277.
   Web of Science ®Google Scholar
• Chhatwal J, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017;65(3):777–788.
   Web of Science ®Google Scholar
• Martin NK, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol. 2016;65(1):17–25.
   PubMed Web of Science ®Google Scholar
• Martin NK, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55(1):49–57.
   PubMed Web of Science ®Google Scholar
• Denton BT, et al. Optimizing the start time of statin therapy for patients with diabetes. Med Decis Mak. 2009;29(3):351–367.
   PubMed Web of Science ®Google Scholar
• WL W. Operations research: applications and algorithms. Belmont, CA: Wadsworth; 1994.
   Google Scholar
• Ministry of justice. Statistics on prison population. 2018. https://www.gov.uk/government/collections/prison-population-statistics
   Google Scholar
• Taylor A, et al. Low incidence of hepatitis C virus among prisoners in Scotland. Addiction. 2013;108(7):1296–1304.
   Web of Science ®Google Scholar
• De Angelis D, et al. An evidence synthesis approach to estimating hepatitis C prevalence in England and Wales. Stat Methods Med Res. 2009;18(4):361–379.
   Web of Science ®Google Scholar
• Kwon JA, et al. Estimating the cost-effectiveness of needle-syringe programs in Australia. Aids. 2012;26(17):2201–2210.
   Web of Science ®Google Scholar
• Platt L, et al. Public Health Research, in Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling. Southampton (UK): NIHR Journals Library; 2017.
   Google Scholar
• Pollack HA. Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users. Med Decis Making. 2001;21(5):357–367.
   Web of Science ®Google Scholar
• Cousien A, et al. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: the case of France. J Viral Hepat. 2018;25(10):1197–1207.
   Web of Science ®Google Scholar
• Cousien A, et al. Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology. 2016;63(4):1090–1101.
   PubMed Web of Science ®Google Scholar
• Jacobs P, Calder P, Taylor M, et al. Cost effectiveness of streetworks’ needle exchange program of Edmonton. Can J Public Health. 1999;90(3):168–171.
   PubMed Web of Science ®Google Scholar
• Jozaghi E, Reid AA, Andresen MA. A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada. Subst Abuse Treat Prev Policy. 2013;8:25.
   PubMed Web of Science ®Google Scholar
• Chen YH, Guigayoma J, McFarland W, et al. Increases in pre-exposure prophylaxis use and decreases in condom use: behavioral patterns among hiv-negative san francisco men who have sex with men, 2004-2017. AIDS Behav; 2018:23(7):1841-1845.
   Google Scholar
• Schmidt HA, McIver R, Houghton R, et al. Nurse-led pre-exposure prophylaxis: a non-traditional model to provide HIV prevention in a resource-constrained, pragmatic clinical trial. Sex Health; 2018;15(6):595-597.
   Google Scholar
• Coelho L, Grinsztejn B, Castilho JL, et al. Mortality in HIV-infected women, heterosexual men, and men who have sex with men in Rio de Janeiro, Brazil: an observational cohort study. The Lancet HIV. 2016;3(10):e490–e498.
   PubMed Web of Science ®Google Scholar
• Asher AK, Portillo CJ, Cooper BA, et al. Clinicians‘ views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs. Subst Use Misuse. 2016;51(9):1218–1223.
   PubMed Web of Science ®Google Scholar
• Peter Vickerman AM, Williams J. Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users. An economic modelling report. 2008.
   Google Scholar
• Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 2006;10(21):1–113.
   Web of Science ®Google Scholar
• Scott N, Stoové M, Wilson DP, et al. Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour. J Int AIDS Soc. 2018;21(1):e25059.
   Google Scholar
• Macgregor L, Desai M, Martin NK, et al. Scaling up screening and treatment for elimination of hepatitis C among men who have sex with men in the era of HIV pre-exposure prophylaxis. EClinicalMedicine. 2020;19:100217.
   Google Scholar
• WHO. Barriers and facilitators to hepatitis C treatment for people who inject drugs. 2012. London School of Hygiene and Tropical Medicine, University of London, UK
   Google Scholar
• Public Health England., Hepatitis C: interventions for case-finding and linkage to care. 2019.
   Google Scholar
• NICE National Institute for Health and Care Excellence. Elbasvir–grazoprevir for treating chronic hepatitis C Technology appraisal guidance [TA413]. 2016.
   Google Scholar
• Berenguer J, Gil-Martin Á, Jarrin I, et al. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: madrid coinfection registry findings. Hepatology. 2018;68(1):32–47.
   PubMed Web of Science ®Google Scholar